Loading search results
A Cross-over Randomised Control Trial Comparing Two Timing of Levothyroxin Intake (Fasting Versus Three Hours After Breakfast) in Well-controlled Hypothyroid Patients: Control of the Disease, Quality of Life and Satisfaction
Sponsor study identifier
interventional
102
1 country
1
Study Start
July 24, 2025
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary hypothyroidism is a common condition, affecting nearly 10% of the general population. Its treatment is levothyroxine, a synthetic thyroid hormone with a half-life of nearly eight days. Optimal absorption of levothyroxine occurs when it is taken on an empty stomach. It is generally recommended to take the medication in the morning, at least 30 minutes before breakfast. However, this treatment regimen can be challenging for some patients. Missed doses constitute a problem, leading some patients to choose another timing of intake. Other patients may find it difficult to wait before breakfast, resulting in suboptimal absorption, increased TSH levels, and poor disease control. Despite these challenges, American Thyroid Association guidelines recommend taking levothyroxine in the morning, in a fasting state, as the preferred timing of intake. They also suggest bedtime intake as a reasonable alternative, as long as the medication is taken at least three hours after the evening meal. As optimal levothyroxine absorption depends primarily on intake on an empty stomach, alternative treatment schedules could be considered, as long as the fasting requirement is respected to maintain stable TSH levels. To our knowledge, only one study has compared daytime levothyroxine intake, three hours after breakfast, with morning and bedtime intake. There was no significant difference in TSH levels between the different schedules. Confirming the stability of TSH levels with different schedules would offer patients with hypothyroidism greater flexibility in treatment timing, better adapted to their lifestyle habits. The aim of our study is to compare serum TSH levels according to two timings of levothyroxine intake in patients with hypothyroidism. Secondary objectives are to assess treatment adherence, quality of life, and patients' preferred timing of levothyroxine intake.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 24, 2025
Actual (reported)September 17, 2025
Actual (reported)October 28, 2026
Actual (reported)December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Stability of TSH levels with both timing of intake
The primary outcome is to compare TSH levels when levothyroxine is taken at fasting, and TSH levels (µUI/mL) when levothyroxine is taken three hours after breakfast. The investigators aim to confirm that TSH levels (µUI/mL)won't change despite the change of timing of intake, and TSH levels (µUI/mL) will be comparable in either group, i.e no significant difference of TSH levels (µUI/mL) regardless of the first arm of levothyroxin intake
From enrollment to 16 weeks after enrollment, with two TSH performed for each patient with a 8 weeks interval
Girerd scale adherence and Likert satisfaction scale to change of timing of intake
from enrollment to 16 weeks after enrollment
In this group, during the first period, patients will take levothyroxine in a fasting state and then wait at least 30 minutes before eating. TSH levels will be measured after eight weeks, with assessment of adherence, satisfaction, and quality of life. During the second period, patients will take levothyroxine three hours after breakfast and avoid eating anything else for at least 30 minutes. TSH levels will be measured after eight weeks, with assessment of adherence, satisfaction, and quality of life. After completion of the two periods, the investigators will ask patients about their preferred timing of levothyroxine intake. Other medications must be taken at least three hours after levothyroxine intake.
In this group, during the first period, patients will take levothyroxine three hours after breakfast and avoid eating anything else for at least 30 minutes. TSH levels will be measured after eight weeks, with assessment of adherence, satisfaction, and quality of life. During the second period, patients will take levothyroxine in a fasting state and then wait at least 30 minutes before eating. TSH levels will be measured after eight weeks, with assessment of adherence, satisfaction, and quality of life. After completion of the two periods, the investigators will ask patients about their preferred timing of levothyroxine intake. Other medications must be taken at least three hours after levothyroxine intake.
Levothyroxine will be taken in a fasting state in the morning, with a waiting time of at least 30 minutes before breakfast. TSH levels will be measured after eight weeks. There will be no washout period. During the second period, levothyroxine will be taken three hours after breakfast, with at least 30 minutes before any further oral intake. TSH levels will be measured after eight weeks.
La Rabta hospital
Tunis, Tunis Governorate, 1053, Tunisia
Melika Chihaoui, Medical professor
University Tunis El Manar
First Submitted
September 17, 2025
First Posted
October 28, 2026
Study Start
July 24, 2025
Actual (reported)Primary Completion
December 2026
EstimatedLevothyroxine will be taken three hours after breakfast, with at least 30 minutes before any further oral intake. TSH levels will be measured after eight weeks. There will be no washout period. During the second period, levothyroxine will be taken in a fasting state in the morning, with a waiting time of at least 30 minutes before breakfast. TSH levels will be measured after eight weeks.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 28, 2026
Record last verified: 2026-10
The investigators will share data regarding the study protocol, the consent form, the arms of study and the primary and secondary outcomes
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: